- Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
Journal of inorganic biochemistry (2011-11-25)
A Bergamo, C Gaiddon, J H M Schellens, J H Beijnen, G Sava
PMID22112845
RÉSUMÉ
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development.
MATÉRIAUX
Référence du produit
Marque
Description du produit
Ruthenium, Ruthenium, foil, 6x6mm, thickness 1.0mm, 99.9%
Ruthenium, Ruthenium, pellets, 5g, max. size 10mm, 99.9%
Ruthenium, Ruthenium, foil, 25x25mm, thickness 1.0mm, 99.9%
Ruthenium, Ruthenium, bar, 50mm x 2mm x 2mm, 99.9%
Ruthenium, Ruthenium, bar, 25mm x 2mm x 2mm, 99.9%
Ruthenium, Ruthenium, foil, 10x10mm, thickness 1.0mm, 99.9%
Ruthenium, Ruthenium, rod, 12.7mm, diameter 12.7mm, 99.9%
Ruthenium, Ruthenium, microfoil, disks, 10mm, thinness 0.1μm, specific density 122μg/cm2, permanent mylar 3.5μm support, 99.9%
Ruthenium, Ruthenium, microfoil, disks, 10mm, thinness 0.025μm, specific density 30.5μg/cm2, permanent mylar 3.5μm support, 99.9%
Ruthenium, Ruthenium, pellets, 2.5g, max. size 10mm, 99.9%